BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 27602236)

  • 1. Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases.
    Soufli I; Toumi R; Rafa H; Touil-Boukoffa C
    World J Gastrointest Pharmacol Ther; 2016 Aug; 7(3):353-60. PubMed ID: 27602236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid.
    Rafa H; Saoula H; Belkhelfa M; Medjeber O; Soufli I; Toumi R; de Launoit Y; Moralès O; Nakmouche M; Delhem N; Touil-Boukoffa C
    J Interferon Cytokine Res; 2013 Jul; 33(7):355-68. PubMed ID: 23472658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of pro-inflammatory cytokine release by selective inhibition of inducible nitric oxide synthase in mucosal explants from patients with ulcerative colitis.
    Kankuri E; Hämäläinen M; Hukkanen M; Salmenperä P; Kivilaakso E; Vapaatalo H; Moilanen E
    Scand J Gastroenterol; 2003 Feb; 38(2):186-92. PubMed ID: 12678336
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Xu YW; Xing RX; Zhang WH; Li L; Wu Y; Hu J; Wang C; Luo QL; Shen JL; Chen X
    World J Gastroenterol; 2019 Dec; 25(45):6634-6652. PubMed ID: 31832003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hispidulin-7-O-Neohesperidoside from
    Park JC; Yoo H; Kim CE; Shim SY; Lee M
    Pharmacogn Mag; 2017; 13(52):707-711. PubMed ID: 29200737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esophagoprotective activity of angiotensin-(1-7) in experimental model of acute reflux esophagitis. Evidence for the role of nitric oxide, sensory nerves, hypoxia-inducible factor-1alpha and proinflammatory cytokines.
    Pawlik MW; Kwiecien S; Pajdo R; Ptak-Belowska A; Brzozowski B; Krzysiek-Maczka G; Strzalka M; Konturek SJ; Brzozowski T
    J Physiol Pharmacol; 2014 Dec; 65(6):809-22. PubMed ID: 25554985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.
    Reinecker HC; Steffen M; Witthoeft T; Pflueger I; Schreiber S; MacDermott RP; Raedler A
    Clin Exp Immunol; 1993 Oct; 94(1):174-81. PubMed ID: 8403503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic targeting in the treatment of inflammatory bowel diseases.
    Bosani M; Ardizzone S; Porro GB
    Biologics; 2009; 3():77-97. PubMed ID: 19707398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoregulatory Pathways Involved in Inflammatory Bowel Disease.
    Fonseca-Camarillo G; Yamamoto-Furusho JK
    Inflamm Bowel Dis; 2015 Sep; 21(9):2188-93. PubMed ID: 26111210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease.
    Cătană CS; Berindan Neagoe I; Cozma V; Magdaş C; Tăbăran F; Dumitraşcu DL
    World J Gastroenterol; 2015 May; 21(19):5823-30. PubMed ID: 26019446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines in inflammatory bowel disease.
    Kmieć Z
    Arch Immunol Ther Exp (Warsz); 1998; 46(3):143-55. PubMed ID: 9704146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Melanocyte-stimulating-hormone (α-MSH) modulates human chondrocyte activation induced by proinflammatory cytokines.
    Capsoni F; Ongari AM; Lonati C; Accetta R; Gatti S; Catania A
    BMC Musculoskelet Disord; 2015 Jun; 16():154. PubMed ID: 26093672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of the mucosal immune system in inflammatory bowel disease.
    MacDermott RP
    J Gastroenterol; 1996 Dec; 31(6):907-16. PubMed ID: 9027661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory cytokines in exhaled breath condensate in children with inflammatory bowel diseases.
    Krenke K; Peradzyńska J; Lange J; Banaszkiewicz A; Łazowska-Przeorek I; Grzela K; Radzikowski A; Kulus M
    Pediatr Pulmonol; 2014 Dec; 49(12):1190-5. PubMed ID: 24339443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence and Implications of the Molecular Paradigm of Nitric Oxide Underlying Inflammatory Reactions of the Gastrointestinal Tract of Dog: A Major Hallmark of Inflammatory Bowel Disease.
    Rana T
    Inflamm Bowel Dis; 2022 Aug; 28(8):1280-1288. PubMed ID: 35312776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High iNOS and IL-1β immunoreactivity are features of colitis-associated colorectal cancer tumors, but fail to predict 5-year survival.
    Björner K; Chen WN; Gannavarapu VR; Axling F; Gulyas M; Halim MA; Webb DL; Hellström PM
    Ups J Med Sci; 2023; 28():. PubMed ID: 38187473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of interferon-γ in bowel disease pathogenesis by nitric oxide pathway: a study in Algerian patients.
    Rafa H; Amri M; Saoula H; Belkhelfa M; Medjeber O; Boutaleb A; Aftis S; Nakmouche M; Touil-Boukoffa C
    J Interferon Cytokine Res; 2010 Sep; 30(9):691-7. PubMed ID: 20626296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation by cytokines of the inducible nitric oxide synthase promoter in insulin-producing cells.
    Darville MI; Eizirik DL
    Diabetologia; 1998 Sep; 41(9):1101-8. PubMed ID: 9754830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoregulatory properties of IL-13 in patients with inflammatory bowel disease; comparison with IL-4 and IL-10.
    Kucharzik T; Lügering N; Weigelt H; Adolf M; Domschke W; Stoll R
    Clin Exp Immunol; 1996 Jun; 104(3):483-90. PubMed ID: 9099934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.